Karuna Therapeutics Correlations
The correlation of Karuna Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak. If the correlation is 0, the equities are not correlated; they are entirely random.
Karuna |
Related Correlations Analysis
| Click cells to compare fundamentals | Check Volatility | Backtest Portfolio |
Correlation Matchups
Over a given time period, the two securities move together when the Correlation Coefficient is positive. Conversely, the two assets move in opposite directions when the Correlation Coefficient is negative. Determining your positions' relationship to each other is valuable for analyzing and projecting your portfolio's future expected return and risk.High positive correlations
| High negative correlations
|
Risk-Adjusted Indicators
There is a big difference between Karuna Stock performing well and Karuna Therapeutics Company doing well as a business compared to the competition. There are so many exceptions to the norm that investors cannot definitively determine what's good or bad unless they analyze Karuna Therapeutics' multiple risk-adjusted performance indicators across the competitive landscape. These indicators are quantitative in nature and help investors forecast volatility and risk-adjusted expected returns across various positions.| Mean Deviation | Jensen Alpha | Sortino Ratio | Treynor Ratio | Semi Deviation | Expected Shortfall | Potential Upside | Value @Risk | Maximum Drawdown | ||
|---|---|---|---|---|---|---|---|---|---|---|
| ISEE | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||
| BPMC | 2.13 | 0.05 | 0.00 | (0.03) | 0.00 | 5.39 | 26.30 | |||
| AMLX | 3.64 | 0.00 | 0.00 | (0.06) | 0.00 | 7.20 | 21.45 | |||
| DAWN | 2.87 | (0.52) | 0.00 | (0.64) | 0.00 | 6.36 | 22.86 | |||
| XFOR | 6.27 | (0.67) | 0.00 | (1.77) | 0.00 | 10.87 | 68.45 | |||
| INZY | 4.07 | (1.42) | 0.00 | (0.89) | 0.00 | 6.82 | 36.29 | |||
| ABOS | 2.99 | (0.64) | 0.00 | (0.59) | 0.00 | 6.57 | 19.77 | |||
| MREO | 2.65 | (0.57) | 0.00 | (0.84) | 0.00 | 6.16 | 20.77 | |||
| TERN | 3.05 | (0.92) | 0.00 | (1.16) | 0.00 | 5.03 | 19.13 | |||
| MRTX | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
View Karuna Therapeutics Related Equities
| Risk & Return | Correlation |
Karuna Therapeutics Corporate Management
| Alexis Smith | Vice Relations | Profile | |
| Stephen Brannan | Chief Medical Officer | Profile | |
| Frank Truslow | Senior Development | Profile | |
| Mia JD | General Counsel | Profile | |
| Ronald MD | Senior Medical | Profile |
Still Interested in Karuna Therapeutics?
Investing in delisted delisted stocks can be risky, as the stock is no longer traded on a public exchange and can therefore be difficult to sell. Delisting typically occurs when a company has failed to meet exchange requirements or has been acquired. Before investing, it's important to thoroughly research the company, including its financial health and prospects for the future, as well as the reasons for its delisting. Additionally, it may be difficult to find accurate and up-to-date information on the company and its stock.